{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:11:35Z","timestamp":1785190295613,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,17]]},"DOI":"10.7759\/cureus.9812","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T18:14:27Z","timestamp":1597688067000},"source":"Crossref","is-referenced-by-count":5,"title":["FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric\/Adolescents in Moderate to Severe Psoriasis? A Systematic Review"],"prefix":"10.7759","author":[{"given":"Nida","family":"Aslam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajra","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salikh","family":"Murtazaliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohail J","family":"Quazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke WH","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015, 386:983-994. 10.1016\/S0140-6736(14)61909-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/PHMT.S75836","article-title":"Efficacy and safety of ustekinumab in adolescents","volume":"7","author":"Kellen R","year":"2016","unstructured":"Kellen R, Silverberg NB, Lebwohl M. Efficacy and safety of ustekinumab in adolescents. Pediatric Health Med Ther. 2016, 7:109. 10.2147\/PHMT.S75836","journal-title":"Pediatric Health Med Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.056","article-title":"Management of pediatric plaque psoriasis using biologics","volume":"82","author":"Lansang P","year":"2020","unstructured":"Lansang P, Bergman, JN, Fiorillo L, et al.. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol. 2020, 82:213-221. 10.1016\/j.jaad.2019.05.056","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: a population-based study","volume":"62","author":"Tollefson MM","year":"2010","unstructured":"Tollefson MM, Crowson CS, McEvoy MT. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010, 62:979-87. 10.1016\/j.jaad.2009.07.029","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0499","article-title":"Pediatric psoriasis comorbidity screening guidelines","volume":"153","author":"Osier E","year":"2017","unstructured":"Osier E, Wang AS, Tollefson MM, et al.. Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatol. 2017, 153:698-704. 10.1001\/jamadermatol.2017.0499","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328348b278","article-title":"Psoriatic juvenile idiopathic arthritis: a tale of two subgroups","volume":"23","author":"Stoll ML","year":"2011","unstructured":"Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011, 23:437-443. 10.1097\/BOR.0b013e328348b278","journal-title":"Curr Opin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0026-8","article-title":"Diagnosis and treatment of pediatric psoriasis: current and future","volume":"14","author":"Shah KN","year":"2013","unstructured":"Shah KN. Diagnosis and treatment of pediatric psoriasis: current and future. Am J Clin Dermatol. 2013, 14:195-213. 10.1007\/s40257-013-0026-8","journal-title":"Am J Clin Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1391787","article-title":"Biologics in pediatric psoriasis-efficacy and safety","volume":"17","author":"Dogra S","year":"2018","unstructured":"Dogra S, Mahajan R. Biologics in pediatric psoriasis-efficacy and safety. Expert Opinion Drug Saf. 2018, 17:9-16. 10.1080\/14740338.2018.1391787","journal-title":"Expert Opinion Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/ijpd.IJPD_72_18","article-title":"Childhood psoriasis: what is new and what is news","volume":"19","author":"Dogra S","year":"2018","unstructured":"Dogra S, Bishnoi A. Childhood psoriasis: what is new and what is news. Indian J Paediatr Dermatol. 2018, 19:308. 10.4103\/ijpd.IJPD_72_18","journal-title":"Indian J Paediatr Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2012.12.005","article-title":"Systemic treatments for severe pediatric psoriasis: a practical approach","volume":"31","author":"Marqueling AL","year":"2013","unstructured":"Marqueling AL, Cordoro KM. Systemic treatments for severe pediatric psoriasis: a practical approach. Dermatol Clin. 2013, 31:267-288. 10.1016\/j.det.2012.12.005","journal-title":"Dermatol Clin"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010017.pub2","article-title":"Anti\u2010TNF agents for pediatric psoriasis","volume":"10","author":"Sanclemente G","year":"2015","unstructured":"Sanclemente G, Murphy R, Contreras J, Garcia H, Cosp XB. Anti\u2010TNF agents for pediatric psoriasis. Cochrane Database of Systematic Reviews. 2015, 10:1002\/14651858. 10.1002\/14651858.CD010017.pub2","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-017-2985-x","article-title":"Treatment of severe psoriasis in children: recommendations of an Italian expert group","volume":"176","author":"Fortina AB","year":"2017","unstructured":"Fortina AB, Bardazzi F, Berti S, et al.. Treatment of severe psoriasis in children: recommendations of an Italian expert group. Eur J Ped. 2017, 176:1339-1354. 10.1007\/s00431-017-2985-x","journal-title":"Eur J Ped"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter A","year":"2020","unstructured":"Menter A, Cordoro KM, Davis DM, et al.. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020, 82:161-201. 10.1016\/j.jaad.2019.08.049","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.04.004","article-title":"Long-term etanercept in pediatric patients with plaque psoriasis","volume":"63","author":"Paller AS","year":"2010","unstructured":"Paller AS, Siegfried EC, Eichenfield LF, et al.. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010, 63:762-768. 10.1016\/j.jaad.2010.04.004","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller AS","year":"2016","unstructured":"Paller AS, Siegfried EC, Pariser DM, et al.. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016, 74:280-287. 10.1016\/j.jaad.2015.09.056","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.10.046","article-title":"Intermittent etanercept therapy in pediatric patients with psoriasis","volume":"63","author":"Siegfried EC","year":"2010","unstructured":"Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol. 2010, 63:769-774. 10.1016\/j.jaad.2009.10.046","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.060","article-title":"Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial","volume":"64","author":"Langley RG","year":"2011","unstructured":"Langley RG, Paller AS, Hebert AA, et al.. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011, 64:64-70. 10.1016\/j.jaad.2010.02.060","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1364692","article-title":"Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study","volume":"29","author":"Di Lernia V","year":"2018","unstructured":"Di Lernia V, Guarneri C, Stingeni L, et al.. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Derm Treat. 2018, 29:217-219. 10.1080\/09546634.2017.1364692","journal-title":"J Derm Treat"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells I","year":"2015","unstructured":"Landells I, Marano C, Hsu MC, et al.. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015, 73:594-603. 10.1016\/j.jaad.2015.07.002","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.3029","article-title":"Safety of systemic agents for the treatment of pediatric psoriasis","volume":"153","author":"Bronckers IM","year":"2017","unstructured":"Bronckers IM, Seyger MM, West DP, Lara-Corrales I, Tollefson M, Tom WL, Siegfried E. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA dermatology. 2017, 153:1147-1157. 10.1001\/jamadermatol.2017.3029","journal-title":"JAMA dermatology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12782","article-title":"Treatment of moderate to severe pediatric psoriasis: a retrospective case series","volume":"33","author":"Klufas DM","year":"2016","unstructured":"Klufas DM, Wald JM, Strober BE. Treatment of moderate to severe pediatric psoriasis: a retrospective case series. Ped Derm. 2016, 33:142-149. 10.1111\/pde.12782","journal-title":"Ped Derm"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4835","article-title":"A comparison of psoriasis severity in pediatric patients treated with methotrexate vs. biologic agents","volume":"156","author":"Bronckers IM","year":"2020","unstructured":"Bronckers IM, Paller AS, West DP, et al.. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs. biologic agents. JAMA Derm. 2020, 156:384-392. 10.1001\/jamadermatol.2019.4835","journal-title":"JAMA Derm"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00335-9","article-title":"Evaluation of children with psoriasis from the BiPe cohort: are patients using biotherapies in real life eligible for phase III clinical studies?","volume":"21","author":"Phan C","year":"2019","unstructured":"Phan C, Beauchet A, Burztejn AC, et al.. Evaluation of children with psoriasis from the BiPe cohort: are patients using biotherapies in real life eligible for phase III clinical studies?. Pediatr Drugs. 2019, 21:169-175. 10.1007\/s40272-019-00335-9","journal-title":"Pediatr Drugs"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12801","article-title":"Pediatric dermatology-critical approach to the new treatments","volume":"32","author":"Liang Y","year":"2019","unstructured":"Liang Y, Chen YL, Zhao MT, et al.. Pediatric dermatology-critical approach to the new treatments. Dermatol Ther. 2019, 32:12801. 10.1111\/dth.12801","journal-title":"Dermatol Ther"},{"key":"ref26","article-title":"Systemic treatment of recalcitrant pediatric psoriasis: a case series and literature review","volume":"14","author":"Garber C","year":"2015","unstructured":"Garber C, Creighton-Smith M, Sorensen EP, Dumont N, Gottlieb AB. Systemic treatment of recalcitrant pediatric psoriasis: a case series and literature review. J Drugs Dermatol. 2015, 14:881-886.","journal-title":"J Drugs Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis","volume":"177","author":"Smith CH","year":"2017","unstructured":"Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al.. British Association of Dermatologists guidelines for biologic therapy for psoriasis. 2017. Br J Dermatol. 2017, 177:628-636. 10.1111\/bjd.15665"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp KA","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et al.. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008, 371:1675-1684. 10.1016\/S0140-6736(08)60726-6","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0117-6","article-title":"Systemic treatment of pediatric psoriasis: a review","volume":"6","author":"Napolitano M","year":"2016","unstructured":"Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N. Systemic treatment of pediatric psoriasis: a review. Dermatol Ther. 2016, 6:125-142. 10.1007\/s13555-016-0117-6","journal-title":"Dermatol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/36763-fda-approved-biologics-can-etanercept-and-ustekinumab-be-considered-a-first-line-systemic-therapy-for-pediatricadolescents-in-moderate-to-severe-psoriasis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:24:36Z","timestamp":1707506676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/36763-fda-approved-biologics-can-etanercept-and-ustekinumab-be-considered-a-first-line-systemic-therapy-for-pediatricadolescents-in-moderate-to-severe-psoriasis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.9812","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,17]]}}}